R3 Stem Cell, a top regenerative medicine company, announced the publication of a systematic review by its Research ...

Stem cell therapy may offer relief for some people with early knee damage or mild osteoarthritis and could help delay surgery ...

The case of a man accused of robbing exotic dancers at gunpoint finally goes to trial. Jurors don't know he's also accused of ...

Many drug and antibody discovery pathways focus on intricately folded cell membrane proteins. When molecules of a drug ...

People report that their personal contact info was surfaced by Google AI—and there’s apparently no easy way to prevent it.

Scientists from EMBL and the University of Virginia discovered a new protein while investigating what happens to yeast cells ...

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Beqalzi (sonrotoclax) is the first BCL2 inhibitor indicated for MCL patients who have progressed after at least 2 lines of therapy, including a BTK inhibitor.

During the quarter Cell Impact continued its work on ongoing customer projects and made progress in line with its updated strategy, with an increased focus on expanding the business and future high-vo ...

Kouri Richins – who published a children’s book about coping with grief following Eric Richins’ death – could be sentenced to ...

BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, ...